Abstract: Poster Presentations |

Bacteriologic Eradication of Haemophilus Influenzae in Patients with Acute Bacterial Exacerbations of Chronic Bronchitis: A Comparison of Moxifloxacin to Macrolide Agents FREE TO VIEW

Michael Niederman, MD*; Antonio Anzueto, MD; Sanjay Sethi, MD; Shurjeel Choudhri, MD; Amar Kureishi, MD; Daniel Haverstock, MS; Renee Perroncel, BS
Author and Funding Information

Winthrop University Hospital, Mineola, NY


Chest. 2004;126(4_MeetingAbstracts):838S. doi:10.1378/chest.126.4_MeetingAbstracts.838S
Text Size: A A A
Published online


PURPOSE:  H. influenzae is the most common pathogen associated with acute bacterial exacerbations of chronic bronchitis (ABECB). With increasing H. influenzae resistance to macrolides new treatment options are needed.

METHODS:  Data were pooled from four double-blind, multicenter, randomized trials comparing moxifloxacin (400mg QD x 5–10d) to macrolides (azithromycin 500mg/250mg QD x 5d, or clarithromycin 500mg BID x 5–10d) in the treatment of ABECB. Clinical and bacteriologic success rates for the efficacy-valid population were recorded at the test-of-cure (TOC) visit (7–37 days post-therapy).

RESULTS:  Of 910 microbiologically valid patients, 292 (32%) patients had infection with H. influenzae. The treatment groups were balanced based on demographic/baseline medical characteristics (62% male, mean age 55 yr, 58% current smokers, 29% past smokers, 61% <<26>2 ABECB previous year). Comparative bacteriologic eradication and clinical success rates for moxifloxacin and macrolide agents are provided below. Moxifloxacin had consistently higher bacteriologic eradication rates than the macrolides in both patients with <<26>2 or >2 exacerbations in the previous year.

CONCLUSION:  For patients with ABECB due to H. influenzae, moxifloxacin consistently provided superior bacteriologic eradication rates than macrolide therapy.

CLINICAL IMPLICATIONS:  The superior bacteriologic eradication rates provided by moxifloxacin in the treatment of H. influenzae-associated ABECB may reduce the risk of antibiotic resistant mutants and prolong the infection-free interval in these patients. Drug ComparisonClinical SuccessP-value*Bacteriologic EradicationP-value*Moxifloxacin vs. Macrolides (Clarithromycin+ Azithromycin)90% (128/143) 85% (127/149)P=0.27893% (133/143) 73% (109/149)P=0.001Moxifloxacin vs. Clarithromycin89% (72/81) 88% (74/84)P=0.87390% (73/81) 64% (54/84)P=0.001Moxifloxacin vs. Azithromycin90% (56/62) 82% (53/65)P=0.15697% (60/62) 85% (55/65)P=0.019*

chi-squared tests

DISCLOSURE:  M. Niederman, Bayer

Wednesday, October 27, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543